Skip to main content
SpringerLink
Log in

Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia

  • Review
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

In view of their antimicrobial activity and pharmacological properties, fluoroquinolones should be suitable for the treatment of lower respiratory tract infections. The overall clinical success rate using enoxacin, ofloxacin, pefloxacin, and ciprofloxacin ranges from 81 % to 89 %. Despite relatively high MICs of the fluoroquinolones forStreptococcus pneumoniae, the clinical success rate of these drugs in pneumococcal infections is 91 %, but the eradication rate of this pathogen is lower (73 %). In addition, fluoroquinolones appeared to be as effective as standard antibiotic regimens for treatment of bronchopulmonary infections in most of the comparative trials reported. The new quinolones could be a good alternative for treatment of acute exacerbations of chronic bronchitis, especially if examination of the sputum reveals gram-negative pathogens. In community-acquired pneumonia, drugs other than quinolones seem indicated because of the limited efficacy of the new quinolones in the treatment of severe pneumococcal infections and the poor activity of these drugs against the anaerobic flora causing aspiration pneumonia. In contrast, new quinolones should be very suitable for treatment of nosocomial pulmonary infections due to gram-negative pathogens. Quinolones used with or without erythromycin and rifampin, might be useful in the treatment of Legionnaires' disease. The role of these drugs in treatment ofChlamydia andRickettsiae infections remains to be defined.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wolfson JS, Hooper DC Fluoroquinolone anti-microbial agents. Clinical Microbiology Reviews 1989, 2: 378–424.

    PubMed  Google Scholar 

  2. Eliopoulos GM, Eliopoulos CT Quinolones Anti-microbial Agents: Activity in vitro. In: Wolfson JS, Hooper DC (ed): Quinolone Antimicrobial Agents. American Society for Microbiology, Washington, DC, 1989, p. 35–70.

    Google Scholar 

  3. Maesen FPV, Davies BI, Teengs JP, Baur C Quinolone antimicrobial agents in acute exacerbations of chronic bronchitis. European Journal of Respiratory Diseases, 1986, 69, Supplement 146: 585–590.

    Google Scholar 

  4. Berré J, Thys JP, Husson M, Gangji D, Klastersky J Penetration of ciprofloxacin in bronchial secretions after intravenous administration. Journal of Anti-microbial Chemotherapy 1988, 22: 499–504.

    Google Scholar 

  5. Marlin GE, Braude PD, Whelan AJ, Somogyi AA Penetration of enoxacin into human bronchial mucosa. American Review of Respiratory Disease 1986, 134: 1209–1212.

    PubMed  Google Scholar 

  6. Schlenkhoff D, Dalhoff A, Knopf HJ, Opferkuch W Penetration of ciprofloxacin into human lung tissue following intravenous injection. Infection 1986, 14: 299–300.

    Article  PubMed  Google Scholar 

  7. Wijnands WJA, Vree TB, Baars AM, van Herwaarden CLA Pharmacokinetics of enoxacin and its penetration into bronchial secretions and lung tissue. Journal of Antimicrobial Chemotherapy 1988, 21, Supplement B: 67–77.

    Google Scholar 

  8. Koga H: High-performance liquid chromatography measurement of antimicrobial concentrations in polymorphonuclear leukocytes. Antimicrobial Agents and Chemotherapy 1987: 1904–1908.

  9. Nicotra MB, Rivera M Chronic bronchitis: when and how to treat. Seminars in Respiratory Infections 1988, 3: 61–71.

    PubMed  Google Scholar 

  10. Wijnands WJA, van Griethuysen AJA, Vree TB, van Klingeren B, van Herwaarden CLA Enoxacin in lower respiratory tract infections. Journal of Antimicrobial Chemotherapy 1986, 18: 719–727.

    PubMed  Google Scholar 

  11. Davies BI, Maesen FPV Respiratory infections: clinical experiences with the new quinolones. Pharmaceutisch Weekblad 1987, 9, Supplement P: 53–57.

    Google Scholar 

  12. Buggy BP, Mathai G, Krainson JP Enoxacin therapy of lower respiratory tract infections. Current Therapeutic Research 1988, 43: 963–968.

    Google Scholar 

  13. Philip-Joet F, Nourrit J, Frances Y, Arnaud A Enoxacin in the treatment of lower respiratory tract infections. Journal of Antimicrobial Chemotherapy 1988, 21, Supplement B: 125–129.

    Google Scholar 

  14. Scarpazza G, Della Torre F, Scaglione F, Fraschini F Efficacy and safety of enoxacin in the treatment of respiratory infections. International Journal of Clinical Pharmacology Research, 1989, 9: 43–47.

    PubMed  Google Scholar 

  15. Prigogine T, Glupezynski Y, Carpiaux JP, Blogie, M, Yourassowsky E, Schmerber JS Enoxacin in acute exacerbations of chronic bronchitis: a comparison with amoxycillin. Journal of Antimicrobial Chemotherapy 1988, 21, Supplement B: 131–136.

    PubMed  Google Scholar 

  16. Maesen FPV, Davies BI, Teengs JP Pefloxacin in acute exacerbations of chronic bronchitis. Journal of Anti-microbial Chemotherapy 1985, 16: 379–388.

    Google Scholar 

  17. Benard Y, Arnaud A, Benhamou D, Muir JF, Lerebours G, David P, Nouvet G, Guerin JC A single daily dose (800 mg) of pefloxacin as second-line therapy for bronchial infections. Reviews of Infectious Diseases, 1989, 11, Supplement 5: 1226.

    Google Scholar 

  18. Lauwers S, Vincken W, Naessens A, Pierard D Efficacy and safety of pefloxacin in the treatment of severe infections in patients hospitalized in intensive care units. Journal of Antimicrobial Chemotherapy 1986, 17, Supplement B: 111–115.

    PubMed  Google Scholar 

  19. Martin C, Gouin F, Fourrier F, Junginger W, Prieur BL Pefloxacin in the treatment of nosocomial lower respiratory tract infections in intensive care patients. Journal of Antimicrobial Chemotherapy 1988, 21: 795–799.

    PubMed  Google Scholar 

  20. Giamarellou H, Perdikaris G, Galanakis N, Davoulos G, Mandragos K, Sfikakis P Pefloxacin versus ceftazidime in the treatment of a variety of gram-negative bacterial infections. Antimicrobial Agents and Chemotherapy 1989, 33: 1362–1367.

    PubMed  Google Scholar 

  21. Vildé JL, Dournon E, Rajagopalan P Inhibition ofLegionella pneumophila multiplication within human macrophages by antimicrobial agents. Antimicrobial Agents and Chemotherapy 1986, 30: 743–748.

    PubMed  Google Scholar 

  22. Dournon E, Rajagopalan P, Vildé JL, Pocidalo JJ Efficacy of pefloxacin in comparison with erythromycin in the treatment of experimental guinea pig legionellosis. Journal of Antimicrobial Chemotherapy 1986, 17, Supplement B: 41–48.

    Google Scholar 

  23. Havlichek D, Pohlod D, Saravolatz L Comparison of ciprofloxacin and rifampicin in experimentalLegionella pneumophila pneumonia. Journal of Antimicrobial Chemotherapy 1987, 20: 875–881.

    PubMed  Google Scholar 

  24. Bertrand A, Janbon F, Jonquet O, Reynes J Infections par les rickettsiales et fluoroquinolones. Pathologie Biologie 1988, 36: 493–495.

    PubMed  Google Scholar 

  25. Grassi C, Grassi GG, Mangiarotti P Clinical efficacy study. Drugs 1987, 34, Supplement 1: 80–82.

    PubMed  Google Scholar 

  26. Saito A, Katsu M, Saito A, Soejima R Ofloxacin in respiratory tract infection: a review of the results of clinical trials in Japan. Drugs 1987, 34, Supplement 1: 83–89.

    PubMed  Google Scholar 

  27. Shah PM, Knothe H Atemwegsinfektionen: klinische Ergebnisse mit Ofloxacin. Infection 1986, 14, Supplement 1: 79–81.

    Article  PubMed  Google Scholar 

  28. Tosto L, Fostini R, Ortelli L, Greco N, Cattini GC Clinical experience with ofloxacin in acute and chronic infections of the lower respiratory tract. Reviews of Infectious Diseases 1988, 10, Supplement 1: 220.

    Google Scholar 

  29. Chidiac C, Leroy O, Beuscart C, Le Chevalier B, Beaucaire G, Mouton Y and group Efficacy and safety of oral ofloxacin for treatment of pneumonia. Reviews of Infectious Diseases 1989, 11, Supplement 5: 1223–1224.

    Google Scholar 

  30. Meek JCE, Maesen FPV, Davies BI A prospective study of ofloxacin in acute exacerbations of chronic respiratory diseases associated withPseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy 1989, 24: 447–453.

    PubMed  Google Scholar 

  31. Forsberg P, Maller R, Nilsson L Comparative study of oral ofloxacin and erythromycin in the treatment of pneumonia. Reviews of Infectious Diseases 1989, 11, Supplement 5: 1229–1230.

    Google Scholar 

  32. Kobayashi H, Takamura K, Kono K, Onodera S, Sasaki N, Nagahama F, Kawakami Y, Honma Y, Matsuzaki M, Tanimura K Comparison of DL-8280 and amoxicillin in the treatment of respiratory tract infections. Kansenshogaku Zasshi 1984, 58: 525–555.

    PubMed  Google Scholar 

  33. Hooton TM: Ofloxacin in the treatment of respiratory tract infections: preliminary findings from the multicenter respiratory research group. Workshop on ofloxacin, Proceedings of the 15th International Congress of Chemotherapy, Istanbul, 1987, p. 15–19.

  34. Chuard C, Regamey C Wirksamkeit und Verträglichkeit von Ofloxacin bei bronchopulmonalen Infektionen im Vergleich zu Amoxicillin. Schweizerische Medizinische Wochenschrift 1989, 119: 1913–1916.

    PubMed  Google Scholar 

  35. Leophonte P, and Group Study: A multicentre open randomized study of ofloxacin versus a usual treatment in acute community acquired pneumonia. In: Rubinstein E, Adam D (ed): Proceedings of the 16th International Congress of Chemotherapy, Jerusalem, 1989, p. 3561–3562.

  36. Lam WK, Chau PY, So SY, Leung YK, Chan JCK, Ip M, Sham K Ofloxacin compared with amoxycillin in treating infective exacerbations in bronchiectasis. Respiratory Medicine 1989, 83: 299–303.

    PubMed  Google Scholar 

  37. Egede F, Kristensen I A clinical comparative study of ofloxacin and pivampicillin in acute exacerbations of chronic bronchitis. Journal of Antimicrobial Chemotherapy 1988, 22, Supplement C: 139–142.

    PubMed  Google Scholar 

  38. Lipsky BA, Durham C, Hanley ME, Hooton TM, Pecoraro RE: Efficacy of ofloxacin vs crythromycin for treatment of lower respiratory infections in adult outpatients. In: Rubinstein E, Adam D (ed): Proceedings of the 16th International Congress of Chemotherapy, Jerusalem, 1989, p. 3581–3583.

  39. Shliamser L, Potasman I, Bassan H: Comparison of ofloxacin and erythromycin for the treatment of patients with beta-lactam resistant pneumonia. In: Rubinstein E, Adam D (ed): Proceedings of the 16th International Congress of Chemotherapy, Jerusalem, 1989, p. 3551.

  40. Fujimori I, Kobayashi Y, Obana M, Saito A, Tomizawa M, Nakayama I, Hiraga Y, Kikuchi K, Yamamoto A, Takebe K Comparative clinical study of ofloxacin and cefaclor in bacterial bronchitis. Kansenshogaku Zasshi 1984, 58: 832–861.

    PubMed  Google Scholar 

  41. Bariffi F, Giacomelli P, Sanduzzi A, Perna F, De Masi AL A comparative study of ofloxacin versus cefazolin in lower respiratory tract infections. International Journal of Clinical Pharmacology Research 1987, 7: 199–201.

    PubMed  Google Scholar 

  42. Harazim H, Wimmer J, Mittermayer HP An open randomised comparison of ofloxacin and doxycycline in lower respiratory tract infections. Drugs 1987, 34, Supplement 1: 71–73.

    Google Scholar 

  43. Kobayashi H Clinical efficacy of ciprofloxacin in the treatment of patients with respiratory tract infections in Japan. American Journal of Medicine 1987, 82, Supplement 4A: 169–173.

    Article  Google Scholar 

  44. Schacht P, Arcieri G, Branolte J, Bruck H, Chysky V et al. Worldwide clinical data on efficacy and safety of ciprofloxacin. Infection 1988, 16, Supplement 1: 29–43.

    Article  PubMed  Google Scholar 

  45. Davies BI, Maesen FPV, Baur C Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis. European Journal of Clinical Microbiology 1986, 5: 226–231.

    PubMed  Google Scholar 

  46. Hoogkamp-Korstanje JAA, Klein SJ Ciprofloxacin in acute exacerbations of chronic bronchitis. Journal of Antimicrobial Chemotherapy 1986, 18: 407–413.

    PubMed  Google Scholar 

  47. Ramirez CA, Bran JL, Mejia CR, Garcia JF Open, prospective study of the clinical efficacy of ciprofloxacin. Antimicrobial Agents and Chemotherapy 1985, 28: 128–132.

    PubMed  Google Scholar 

  48. Raoof S, Wollschlager C, Khan F Treatment of respiratory tract infections with ciprofloxacin. Journal of Antimicrobial Chemotherapy 1986, 18, Supplement D: 139–145.

    Google Scholar 

  49. Ernst JA, Sy ER, Colon-Lucca H, Sandhu N, Rallos T, Lorian V Ciprofloxacin in the treatment of pneumonia. Antimicrobial Agents and Chemotherapy 1986, 29: 1088–1089.

    PubMed  Google Scholar 

  50. Fass RJ Efficacy and safety of oral ciprofloxacin in the treatment of serious respiratory infections. American Journal of Medicine 1987, 82, Supplement 4A: 202–207.

    Article  Google Scholar 

  51. Chrysanthopoulos CJ, Skoutelis AT, Starakis JC, Anastassiou ED, Bassaris HP Use of intravenous ciprofloxacin in respiratory tract infections and biliary sepsis. American Journal of Medicine 1987, 82, Supplement 4A: 357–359.

    Article  PubMed  Google Scholar 

  52. Salvati F, Zubiani M, Antilli A, Carosi M, Bianchi W, Minniti R, Nunziati F, Spano A Ciprofloxacin in the oral treatment of severe respiratory tract infections. Reviews of Infectious Diseases 1988, 10, Supplement 1: 220–221.

    Google Scholar 

  53. Peloquin CA, Cumbo TJ, Nix DE, Sands MF, Schentag JJ Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Archives of Internal Medicine 1989, 149: 2269–2273.

    Article  PubMed  Google Scholar 

  54. Trenholme GM, Schmitt BA, Spear J, Gvazdinskas LC, Levin S Randomized study of intravenous/oral ciprofloxacin versus ceftazidime in the treatment of hospital and nursing home patients with lower respiratory tract infections. American Journal of Medicine 1989, 87, Supplement 5A: 116–118.

    Article  Google Scholar 

  55. Unertl KE, Lenhart FP, Forst H, Vogler G, Wilm V, Ehret W, Ruckdeschel G Brief report: ciprofloxacin in the treatment of legionellosis in critically ill patients including those cases unresponsive to erythromycin. American Journal of Medicine 1989, 87, Supplement 5A: 128–131.

    Article  Google Scholar 

  56. Kurz RW, Graninger W, Egger TP, Pichler H, Tragl KH Failure of treatment of legionella pneumonia with ciprofloxacin. Journal of Antimicrobial Chemotherapy 1988, 22: 389–391.

    PubMed  Google Scholar 

  57. Hooper TL, Gould FK, Swinburn CR, Featherstone G, Odom NJ et al Ciprofloxacin: a preferred treatment for legionella infections in patients receiving cyclosporin A. Journal of Antimicrobial Chemotherapy 1988, 22: 952–953.

    PubMed  Google Scholar 

  58. Winter JH, McCartney C, Bingham J, Telfer M, White LO, Fallon RJ Ciprofloxacin in the treatment of severe legionnaires' disease. Reviews of Infectious Diseases 1988, 10, Supplement 1: 218–219.

    PubMed  Google Scholar 

  59. Raoult D, Gallais H, De Micco P, Casanova P Ciprofloxacin therapy for Mediterranean spotted fever. Antimicrobial Agents and Chemotherapy 1986, 30: 606–607.

    PubMed  Google Scholar 

  60. Arcieri G, Griffith E, Gruenwaldt G, Heyd A, O'Brien B, Becker N, August R Ciprofloxacin: an update on clinical experience. American Journal of Medicine 1987, 82, Supplement 4A: 381–386.

    Google Scholar 

  61. Wollschlager CM, Raoff S, Khan FA, Guarneri JJ, LaBombardi V, Afzal Q Controlled, comparative study of ciprofloxacin versus ampicillin in treatment of bacterial respiratory tract infections. American Journal of Medicine 1987, 82, Supplement 4A: 164–168.

    PubMed  Google Scholar 

  62. Chodosh S, Tuck J, Stottmeier KD, Pizzuto D Comparison of ciprofloxacin with ampicillin in acute infectious exacerbations of chronic bronchitis. American Journal of Medicine 1989, 87, Supplement 5A: 107–112.

    Article  Google Scholar 

  63. Khan F, Basir R, Afzal Q Controlled, comparative study of low-dose ciprofloxacin vs. ampicillin for respiratory tract infections. Reviews of Infectious Diseases 1989, 11, Supplement 5: 1227–1228.

    Google Scholar 

  64. Gleadhill IC, Ferguson WP, Lowry RC Efficacy and safety of ciprofloxacin in patients with respiratory infections in comparison with amoxycillin. Journal of Antimicrobial Chemotherapy 1986, 18, Supplement D: 133–138.

    Google Scholar 

  65. Schmidt EW, Zimmermann I, Ritzerfeld W, Voss E, Ulmer WT Controlled prospective study of oral amoxycillin/clavulanate vs ciprofloxacin in acute exacerbations of chronic bronchitis. Journal of Antimicrobial Chemotherapy 1989, 24, Supplement B: 185–193.

    PubMed  Google Scholar 

  66. Bantz PM, Grote J, Peters-Haertel W, Stahmann J, Timm J, Kasten R, Bruck H Low-dose ciprofloxacin in respiratory tract infections: randomized comparison with doxycycline in general practice. American Journal of Medicine 1987, 82, Supplement 4A: 208–210.

    Google Scholar 

  67. Feist H, Vetter N, Drlicek M, Otupal I, Weuta H Comparative study of ciprofloxacin and cefalexin in the treatment of patients with lower respiratory tract infections. In: Neu HC, Weuta H (ed): Proceedings of the First International Ciprofloxacin Workshop. Excerpta Medica, Amsterdam, 1986, p. 265–267.

    Google Scholar 

  68. Kobayashi H, Takamura K, Takeda H, Kono K, Saito A Comparative clinical study of ciprofloxacin and cefaclor in the treatment of respiratory tract infections. Chemotherapy 1986, 34: 1011–1037.

    Google Scholar 

  69. Peterson PK, Stein D, Guay DRP, Logan G, Obaid S, Gruninger R, Davies S, Breitenbucher R Prospective study of lower respiratory tract infections in an extended-care nursing home program: potential role of oral ciprofloxacin. American Journal of Medicine 1988, 85: 164–171.

    PubMed  Google Scholar 

  70. Magnani C, Fregni S, Valli G, Cosentina R, Biseetti A Comparative clinical study of ciprofloxacin and cotrimoxazole in respiratory tract infections. In: Neu HC, Weuta H (ed): Proceedings of the First International Ciprofloxacin Workshop. Excerpta Medica, Amsterdam, 1986, p. 265–267.

    Google Scholar 

  71. Canton P, Hoen B, Richet H, Ravoire S, Acar JF Brief report: comparative efficacy of ciprofloxacin versus josamycin in the treatment of acute, recurrent, or exacerbated bronchitis. American Journal of Medicine 1989, 87, Supplement 5A: 121–122.

    Article  PubMed  Google Scholar 

  72. Lode H, Wiley R, Höffken G, Wagner J, Borner K Prospective randomized controlled study of ciprofloxacin versus imipenem-cilastatin in severe clinical infections. Antimicrobial Agents and Chemotherapy 1987, 31: 1491–1496.

    PubMed  Google Scholar 

  73. Haddow A, Greene S, Heinz G, Wantuck D Ciprofloxacin (intravenous/oral) versus ceftazidime in lower respiratory tract infections. American Journal of Medicine 1989, 87, Supplement 5A: 113–115.

    Article  Google Scholar 

  74. Menon L, Ernst JA, Sy ER, Flores D, Pacia A, Lorian V Brief report: sequential intravenous/oral ciprofloxacin compared with intravenous ceftazidime in the treatment of serious lower respiratory tract infections. American Journal of Medicine 1989, 87, Supplement 5A: 119–120.

    Article  Google Scholar 

  75. Levine DP, McNeil P, Lerner SA Randomized, double-blind comparative study of intravenous ciprofloxacin versus ceftazidime in the treatment of serious infections. American Journal of Medicine 1989, 87, Supplement 5A: 160–163.

    Article  PubMed  Google Scholar 

  76. Khan FA, Basir R Sequential intravenous-oral administration of ciprofloxacin vs ceftazidime in serious bacterial respiratory tract infections. Chest 1989, 96: 528–537.

    PubMed  Google Scholar 

  77. Vanderdonckt J, Hellebrand A, Cordier R Clinical evaluation of pefloxacin in community-acquired lower respiratory tract infections. Current Therapeutic Research 1988, 43: 82–91.

    Google Scholar 

  78. Jensen T, Pedersen SS, Nielsen CH, Hoiby N, Koch C The efficacy and safety of ciprofloxacin and ofloxacin in chronicPseudomonas aeruginosa infection in cystic fibrosis. Journal of Antimicrobial Chemotherapy 1987, 20: 585–594.

    PubMed  Google Scholar 

  79. Cooper B, Lawlor M Pneumococcal bacteremia during ciprofloxacin therapy for pneumococcal pneumonia. American Journal of Medicine 1989, 87: 475.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Infectious Disease Clinic, Erasme University Hospital, Route de Lennik 808, 1070, Brussels, Belgium

    J. P. Thys, F. Jacobs & B. Byl

Authors
  1. J. P. Thys
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Jacobs
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Byl
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thys, J.P., Jacobs, F. & Byl, B. Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 10, 304–315 (1991). https://doi.org/10.1007/BF01967004

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01967004

Keywords

Search

Navigation